Impact of amyloidosis on outcomes after transcatheter aortic valve implantation
Revista Española de Cardiología (English Edition) · 2025
DOI: 10.1016/j.rec.2025.01.012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Revista Española de Cardiología (English Edition), 2025. Verfasst von Luigi Gerra und 9 weiteren Autor:innen. Beteiligte Einrichtung: Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University, and Liverpool Heart & Chest Hospital, Liver…. Hauptthemen laut MEDLINE: Transcatheter Aortic Valve Replacement, Amyloidosis, Aortic Valve Stenosis, Postoperative Complications. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
INTRODUCTION AND OBJECTIVES: Data on the impact of amyloidosis on outcomes after transcatheter aortic valve implantation (TAVI) are limited. The objective of this study was to evaluate the 1-year risk of adverse events post-TAVI in patients with amyloidosis. METHODS: Patients undergoing TAVI (between 2005 and 2023) were categorized into 2 groups based on the presence of amyloidosis. The primary outcome was the 1-year risk of a composite endpoint: heart failure (HF), ischemic stroke, pacemaker implantation, acute kidney injury, and all-cause death. Secondary outcomes assessed the individual components of the composite. Propensity score matching was used to balance the groups, and Cox regression was used to assess the risk of adverse outcomes associated with amyloidosis. Composite outcomes were analyzed for early (30-days) and long-term (30-days to 1 year) follow-up. RESULTS: Data from 589 TAVI patients with amyloidosis (mean age 78.9±8.2 years, 31.9% female) were compared with 52 296 individuals without amyloidosis (mean age 78.1±8.8 years, 40.3% female). After propensity score matching, patients with amyloidosis had a significantly higher 1-year risk of adverse events (HR, 1.27; 95%CI, 1.08-1.49). Specifically, patients with amyloidosis showed an increased risk of HF (HR, 1.37; 95%CI, 1.10-1.70). Stroke risk (HR, 1.67; 95%CI, 1.16-2.40) and pacemaker implantation (HR, 2.25; 95%CI, 1.15-4.41) were higher during long-term follow-up, while no differences were found for acute kidney injury or all-cause mortality between the 2 groups. CONCLUSIONS: Among patients undergoing TAVI, those with amyloidosis are at a higher risk of adverse events, particularly HF, and have an increased risk of pacemaker implantation and stroke in the long-term.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University, and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; Divisione di Cardiologia, Dipartimento di Scienz…
- Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University, and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; Dipartimento di Scienze Internistiche, Anestesio…
- Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University, and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom.
- Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University, and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; Department of Basic Science, Prince Sultan Bin A…
- Divisione di Cardiologia, Dipartimento di Scienze Biomediche, Metaboliche e Neuroscienze, Università di Modena e Reggio Emilia, Policlinico di Modena, Modena, Italy.
- Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University, and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; Department of Clinical Medicine, Danish Center f…
Zitieren
APA
Gerra, L., Bucci, T., Lam, H. M., Mantovani, M., Argyris, A. A., Alobaida, M., Sandhu, K., Mills, J., Boriani, G., & Lip, G. Y. H. (2025). Impact of amyloidosis on outcomes after transcatheter aortic valve implantation. Revista Española de Cardiología (English Edition). https://doi.org/10.1016/j.rec.2025.01.012
Vancouver
Gerra L, Bucci T, Lam HM, Mantovani M, Argyris AA, Alobaida M, et al. Impact of amyloidosis on outcomes after transcatheter aortic valve implantation. Revista Española de Cardiología (English Edition). 2025. doi:10.1016/j.rec.2025.01.012
BibTeX
@article{Gerra2025,
author = {Gerra, Luigi and Bucci, Tommaso and Lam, Ho Man and Mantovani, Marta and Argyris, Antonios A and Alobaida, Muath and Sandhu, Kully and Mills, Joseph and Boriani, Giuseppe and Lip, Gregory Y H},
title = {Impact of amyloidosis on outcomes after transcatheter aortic valve implantation},
journal = {Revista Española de Cardiología (English Edition)},
year = {2025},
doi = {10.1016/j.rec.2025.01.012}
}
EUVIMED